Anti-neutrophil cytoplasmic antibody positive vasculitis

2 trials 2 recruiting MedDRA PT
2 Registered trials
2 Recruiting
2 Unique sponsors
3 Unique IMPs
1 Commercial trials
Drug classes (ATC)
L Oncology (ATC L) 2
H Endocrinology (ATC H) 1
Mechanism of action (INN-stem analysis)
Complement inhibitor (C5aR) 1 substance
Corticosteroid 1 substance
Monoclonal antibody (chimeric) 1 substance
Phase III: 1 Phase IV: 1

Filter these 2 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 2 trials

Phase III

1 trial
  • Hospices Civils De Lyon Academic
    PREDNISONE; RITUXIMAB
    2024-514156-33-00 1 country 2019 n=146
    Recruiting

Phase IV

1 trial
  • Amgen Inc. Commercial
    AVACOPAN
    2023-503184-42-00 7 countries 2025 n=47 Orphan
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Amgen Inc. Commercial 1 Phase IV 1
Hospices Civils De Lyon Academic 1 Phase III 1
New trials by year
2019
1
2025
1
← All indication landscapes